Genmab A's

The company operates in a competitive environment marked by rapid technological advancements and a strong focus on intellectual property within the cancer drug sector. It faces competition from large and specialty pharmaceutical and biotechnology companies, academic research institutions, governmental agencies, and both public and private research organizations. Competitors often possess greater financial resources and expertise in research and development, manufacturing, clinical trials, and marketing. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors. Smaller or early-stage companies can also be significant competitors, particularly through collaborations with larger firms. Competition extends to recruiting qualified personnel, establishing clinical trial sites, patient registration, and acquiring complementary technologies. The company co-develops and co-commercializes epcoritamab with AbbVie, utilizing technology licensed from Medarex, Inc. AbbVie and Medarex, Inc. are identified as collaborators or licensors in the development of epcoritamab.